192 related articles for article (PubMed ID: 2166820)
1. Characterization and significance of delayed processing of the feline leukemia virus FeLV-FAIDS envelope glycoprotein.
Poss ML; Quackenbush SL; Mullins JI; Hoover EA
J Virol; 1990 Sep; 64(9):4338-45. PubMed ID: 2166820
[TBL] [Abstract][Full Text] [Related]
2. Posttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirus.
Poss ML; Mullins JI; Hoover EA
J Virol; 1989 Jan; 63(1):189-95. PubMed ID: 2535725
[TBL] [Abstract][Full Text] [Related]
3. Distinct superinfection interference properties yet similar receptor utilization by cytopathic and noncytopathic feline leukemia viruses.
Reinhart TA; Ghosh AK; Hoover EA; Mullins JI
J Virol; 1993 Sep; 67(9):5153-62. PubMed ID: 8394443
[TBL] [Abstract][Full Text] [Related]
4. Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains.
Gwynn SR; Hankenson FC; Lauring AS; Rohn JL; Overbaugh J
J Virol; 2000 Jul; 74(13):5754-61. PubMed ID: 10846053
[TBL] [Abstract][Full Text] [Related]
5. In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant.
Rohn JL; Moser MS; Gwynn SR; Baldwin DN; Overbaugh J
J Virol; 1998 Apr; 72(4):2686-96. PubMed ID: 9525586
[TBL] [Abstract][Full Text] [Related]
6. The host range and interference properties of two closely related feline leukemia variants suggest that they use distinct receptors.
Moser M; Burns CC; Boomer S; Overbaugh J
Virology; 1998 Mar; 242(2):366-77. PubMed ID: 9514965
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS.
Quackenbush SL; Donahue PR; Dean GA; Myles MH; Ackley CD; Cooper MD; Mullins JI; Hoover EA
J Virol; 1990 Nov; 64(11):5465-74. PubMed ID: 1976822
[TBL] [Abstract][Full Text] [Related]
8. Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS.
Donahue PR; Quackenbush SL; Gallo MV; deNoronha CM; Overbaugh J; Hoover EA; Mullins JI
J Virol; 1991 Aug; 65(8):4461-9. PubMed ID: 1649341
[TBL] [Abstract][Full Text] [Related]
9. Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses.
Donahue PR; Hoover EA; Beltz GA; Riedel N; Hirsch VM; Overbaugh J; Mullins JI
J Virol; 1988 Mar; 62(3):722-31. PubMed ID: 2828667
[TBL] [Abstract][Full Text] [Related]
10. Replication kinetics and cell tropism of an immunosuppressive feline leukaemia virus.
Quackenbush SL; Mullins JI; Hoover EA
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1411-20. PubMed ID: 8757981
[TBL] [Abstract][Full Text] [Related]
11. Structure and pathogenicity of individual variants within an immunodeficiency disease-inducing isolate of FeLV.
Overbaugh J; Hoover EA; Mullins JI; Burns DP; Rudensey L; Quackenbush SL; Stallard V; Donahue PR
Virology; 1992 Jun; 188(2):558-69. PubMed ID: 1316674
[TBL] [Abstract][Full Text] [Related]
12. Delayed cytopathicity of a feline leukemia virus variant is due to four mutations in the transmembrane protein gene.
Thomas E; Overbaugh J
J Virol; 1993 Oct; 67(10):5724-32. PubMed ID: 8396654
[TBL] [Abstract][Full Text] [Related]
13. Analysis of FeLV-FAIDS provirus burden and productive infection in lymphocyte subsets in vivo.
Quackenbush SL; Dean GA; Mullins JI; Hoover EA
Virology; 1996 Sep; 223(1):1-9. PubMed ID: 8806534
[TBL] [Abstract][Full Text] [Related]
14. Recombination between feline leukemia virus subgroup B or C and endogenous env elements alters the in vitro biological activities of the viruses.
Pandey R; Ghosh AK; Kumar DV; Bachman BA; Shibata D; Roy-Burman P
J Virol; 1991 Dec; 65(12):6495-508. PubMed ID: 1658356
[TBL] [Abstract][Full Text] [Related]
15. Interference with superinfection and with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins.
Kristal BS; Reinhart TA; Hoover EA; Mullins JI
J Virol; 1993 Jul; 67(7):4142-53. PubMed ID: 8389921
[TBL] [Abstract][Full Text] [Related]
16. Feline leukemia virus subgroup C phenotype evolves through distinct alterations near the N terminus of the envelope surface glycoprotein.
Brojatsch J; Kristal BS; Viglianti GA; Khiroya R; Hoover EA; Mullins JI
Proc Natl Acad Sci U S A; 1992 Sep; 89(18):8457-61. PubMed ID: 1326757
[TBL] [Abstract][Full Text] [Related]
17. The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome.
Bolin LL; Ahmad S; Levy LS
Vet Immunol Immunopathol; 2011 Oct; 143(3-4):221-6. PubMed ID: 21764142
[TBL] [Abstract][Full Text] [Related]
18. Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum.
Chandhasin C; Coan PN; Levy LS
J Virol; 2005 Feb; 79(3):1351-60. PubMed ID: 15650161
[TBL] [Abstract][Full Text] [Related]
19. Unique long terminal repeat and surface glycoprotein gene sequences of feline leukemia virus as determinants of disease outcome.
Chandhasin C; Coan PN; Pandrea I; Grant CK; Lobelle-Rich PA; Puetter A; Levy LS
J Virol; 2005 May; 79(9):5278-87. PubMed ID: 15827142
[TBL] [Abstract][Full Text] [Related]
20. FeLV-FAIDS-induced immunodeficiency syndrome in cats.
Mullins JI; Hoover EA; Overbaugh J; Quackenbush SL; Donahue PR; Poss ML
Vet Immunol Immunopathol; 1989 May; 21(1):25-37. PubMed ID: 2549691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
